Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

Background: Triple-negative breast cancer (TNBC) is a biologically diverse disease, with characteristics such as homologous recombination deficiency (HRD), gene mutation, and immune reactions. Japan Breast Cancer Research Group 22 is a multicenter trial examining TNBC’s response to neoadjuvant chemo...

Full description

Bibliographic Details
Main Authors: Aogi, K. (Author), Bando, H. (Author), Chiba, T. (Author), Haga, H. (Author), Ikarashi, D. (Author), Kadoya, T. (Author), Kawaguchi, K. (Author), Kitano, S. (Author), Masuda, N. (Author), Morita, S. (Author), Nagai, S. (Author), Nakayama, T. (Author), Ohno, S. (Author), Ohtani, S. (Author), Saji, S. (Author), Takahashi, M. (Author), Toi, M. (Author), Ueno, T. (Author), Velaga, R. (Author), Yamanaka, T. (Author), Yamashita, M. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
anthracycline
Anthracyclines
antineoplastic agent
Antineoplastic Combined Chemotherapy Protocols
BRCA1/2
carboplatin
Carboplatin
CD8+ T lymphocyte
CD8-Positive T-Lymphocytes
clinical trial
Eribulin
genetics
homologous recombination
Homologous Recombination
Homologous recombination deficiency (HRD)
human
Humans
Immune microenvironment
Japan
multicenter study
Neoadjuvant chemotherapy
neoadjuvant therapy
Neoadjuvant Therapy
paclitaxel
Paclitaxel
pathology
Platinum
procedures
triple negative breast cancer
Triple Negative Breast Neoplasms
Triple-negative breast cancer
tumor microenvironment
Tumor Microenvironment
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items